Literature DB >> 1011076

Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses.

A P Géradin, F V Abadie, J A Campestrini, W Theobald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1011076     DOI： 10.1007/bf01064556

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  6 in total

1.  GLC determination of carbamazepine suitable for pharmacokinetic studies.

Authors:  A Gérardin; F Abadie; J Laffont
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

3.  Pharmacokinetics of carbamazepine in normal man.

Authors:  R H Levy; W H Pitlick; A S Troupin; J R Green; J M Neal
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

4.  Preliminary observations of serum carbamazepine concentration in epileptic patients.

Authors:  J J Cereghino; J C Meter; J T Brock; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1973-04       Impact factor: 9.910

5.  Distribution and elimination kinetics of carbamazepine in man.

Authors:  M D Rawlins; P Collste; L Bertilsson; L Palmér
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

6.  Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy.

Authors:  S I Johannessen; R E Strandjord
Journal:  Epilepsia       Date:  1973-12       Impact factor: 5.864
  6 in total
  13 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Comparative bioavailability of two commercial preparations of carbamazepine tablets.

Authors:  M Anttila; P Kahela; M Panelius; T Yrjänä; R Tikkanen; R Aaltonen
Journal:  Eur J Clin Pharmacol       Date:  1979-07       Impact factor: 2.953

3.  The pharmacokinetics of carbamazepine.

Authors:  L M Cotter; M J Eadie; W D Hooper; C M Lander; G A Smith; J H Tyrer
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

4.  Time course of carbamazepine self-induction.

Authors:  P J McNamara; W A Colburn; M Gibaldi
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

6.  Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans.

Authors:  M A Nitsche; K Fricke; U Henschke; A Schlitterlau; D Liebetanz; N Lang; S Henning; F Tergau; W Paulus
Journal:  J Physiol       Date:  2003-08-29       Impact factor: 5.182

7.  Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial.

Authors:  A Kayali; I Tuğlular; M Ertaş
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

8.  Differential effects on fast and slow spindle activity, and the sleep slow oscillation in humans with carbamazepine and flunarizine to antagonize voltage-dependent Na+ and Ca2+ channel activity.

Authors:  Amr Ayoub; Dominic Aumann; Anne Hörschelmann; Atossa Kouchekmanesch; Pia Paul; Jan Born; Lisa Marshall
Journal:  Sleep       Date:  2013-06-01       Impact factor: 5.849

9.  Investigating Oral Absorption of Carbamazepine in Pediatric Populations.

Authors:  Philip Kohlmann; Cordula Stillhart; Martin Kuentz; Neil Parrott
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

10.  The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.

Authors:  J Posner; A Bye; K Dean; A W Peck; P D Whiteman
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.